Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted therapies, particularly small-molecule kinase inhibitors, have transformed cancer treatment for specific molecularly defined patient groups.
• Despite initial dramatic responses, therapeutic resistance (primary or acquired) is a significant challenge limiting long-term efficacy.
• Understanding resistance mechanisms is crucial for developing effective treatment strategies.

Purpose of the Study:

• To provide a concise overview of the complex problem of therapeutic resistance to kinase inhibitors.
• To focus on resistance mechanisms in specific cancers: EGFR-mutant/ALK-rearranged non-small cell lung cancer, BRAF-mutant melanoma, and BCR-ABL-positive chronic myeloid leukemia.
• To review emerging strategies aimed at delaying or overcoming drug resistance.

Main Methods:

• Literature review of primary and acquired resistance mechanisms.
• Focus on specific examples of kinase inhibitor resistance in selected malignancies.
• Discussion of current and future therapeutic strategies.

Main Results:

• Primary resistance can stem from tumor-intrinsic factors or patient/drug-specific elements.
• Acquired resistance mechanisms include target gene modification, activation of bypass signaling pathways, and histologic transformation.
• Specific resistance patterns are observed in EGFR-mutant NSCLC, ALK-rearranged NSCLC, BRAF-mutant melanoma, and CML.

Conclusions:

• Therapeutic resistance is a multifaceted challenge in targeted cancer therapy.
• Identifying and understanding diverse resistance mechanisms is key to improving patient outcomes.
• Developing novel strategies to overcome resistance is essential for durable clinical responses.